Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

NCT07282912 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT07282912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07282912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Recruiting
Start date
June 2, 2026
Completion date
June 30, 2028
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ampullary adenocarcinoma, duodenal adenocarcinoma, esophageal adenocarcinoma, foregut adenocarcinoma, gallbladder adenocarcinoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma, intra - and extrahepatic cholangiocarcinoma, pancreas adenocarcinoma